During the study period, a further 11 patients with COVID 19 infection required NIV for type 2 respiratory failure due to pre-existing respiratory conditions. Most of these patients had a documented DNAR decision on admission, however their survival rate was 66.7%.  Therefore, our study results cannot be generalised to patients requiring NIV for hypercapnic respiratory failure in the context of COVID-19 infection.